Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Ertugliflozin

29-08-2021 | ESC 2021 | Conference coverage | News

Metformin use may not influence SGLT2 inhibitor effect

Post-hoc analysis of the VERTIS-CV trial indicates that the cardiovascular effects of ertugliflozin are unaffected by whether people are also taking metformin.

12-10-2020 | Ertugliflozin | Highlight | News

VERTIS CV secondary analyses indicate ertugliflozin protection against HF

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

24-09-2020 | EASD 2020 | Conference coverage | News

Further VERTIS-CV analysis supports ertugliflozin renal benefits

The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the SGLT2 inhibitor medication class.

16-06-2020 | ADA 2020 | Conference coverage | News

VERTIS-CV: Similar MACE risk with ertugliflozin vs placebo in type 2 diabetes

Patients with type 2 diabetes and established atherosclerotic disease who are treated with the SGLT2 inhibitor ertugliflozin have a similar risk for major adverse cardiovascular events to those given placebo, shows the VERTIS-CV trial.

12-06-2017 | Medications | ADA 2017 | News

Research round-up: medications for type 2 diabetes

One of the final sessions on Saturday featured the presentation of new, and mostly positive, data on medications for glycemic control in patients with type 2 diabetes.

Image Credits